Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)

被引：35

作者：

Vuky, Jacqueline

Balar, Arjun Vasant

Castellano, Daniel E.

O'Donnell, Peter H.

Grivas, Petros

Bellmunt, Joaquim

Powles, Thomas

Bajorin, Dean F.

Hahn, Noah M.

De Wit, Ronald

Savage, Mary

Pang, Lei

Frenkl, Tara L.

Keefe, Stephen Michael

Plimack, Elizabeth R.

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR USA

[2] NYU Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA

[3] Hosp Univ 12 Octubre, Madrid, Spain

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Cleveland Clin, Cleveland, OH 44106 USA

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Queen Mary Univ London, Barts Canc Inst, London, England

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[10] Erasmus MC Canc Inst, Rotterdam, Netherlands

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4524

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4524

引用

页数：2